Bristol melanoma drug combo marks new advance in immunotherapy

By Julie Steenhuysen CHICAGO (Reuters) – Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body’s immune system to fight cancer. Bristol released preliminary data from the early-stage trial on Wednesday, with more detailed results expected to highlight the American Society of Clinical Oncology’s annual meeting in Chicago that starts at the end of the month. …